News | October 27, 2022
Dabur India posts consolidated Q2 FY2023 PAT at Rs. 490.06 Cr
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
The company has reported total income of Rs. 3109.77 crores during the period ended September 30, 2022
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
The company has reported total income of Rs. 1612.60 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
Revenue from operations up 26% to Rs. 768 crores
He also highlighted the need for community awareness for continued implementation of the Covid Appropriate Behaviour (CAB) especially in view of the upcoming festival season
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
68% of children on a higher dose of Dupixent achieved histological disease remission at week 16
Subscribe To Our Newsletter & Stay Updated
